Medical device manufacturers operating in the U.S. are facing a fundamental regulatory shift: The Quality System Regulation (QSR) is being replaced by the Quality Management System Regulation (QMSR).
This change aligns U.S. requirements more closely with international practices, particularly ISO 13485:2016, but brings with it additional obligations. While certification to ISO 13485 remains optional, compliance with both ISO 13485 and the new FDA-specific clauses is mandatory.
Special thanks to Seratos' Danièle Grondines for her insights on leadership helping medical device manufacturers navigate the transition to FDA's QMSR with clarity, shared at a recent joint webinar with DQS.
Let’s be clear: ISO 13485 certification is not a legal requirement under QMSR. But compliance is. And the bar has been raised: In addition to full alignment with ISO 13485, manufacturers must address U.S.-specific additions, such as:
This means that even ISO 13485-certified organizations need to perform a focused gap assessment to identify compliance gaps with the new QMSR framework.
Although the QMSR Final Rule has been published, enforcement will take time. But the earlier organizations begin to align, the better their inspection readiness and regulatory resilience will be.
Here’s what a typical transition plan should include:
For organizations operating in multiple markets, aligning QMSR with MDSAP and EU MDR audits isn’t just possible – it’s strategic. Integrated audits reduce effort, support global compliance, and ensure consistency across jurisdictions.
QMSR isn’t just a new rulebook. It’s part of a broader shift toward risk-based, globally harmonized quality systems – and an opportunity for forward-thinking organizations to modernize their operations.
Dr. Yuan Li holds a doctorate in Mechanical Engineering and has published 13 studies on spinal pathologies and implant innovation. He built his career in Regulatory Affairs, guiding 510(k) and CE certifications across the U.S., EU, and APAC regions. Since joining the notified body sector in 2015, he has advanced from orthopedic product reviewer to management, now overseeing North American operations with a focus on market growth and compliance.
